Alison Harrod

827 total citations
9 papers, 416 citations indexed

About

Alison Harrod is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Alison Harrod has authored 9 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 3 papers in Cancer Research and 2 papers in Oncology. Recurrent topics in Alison Harrod's work include Genomics and Chromatin Dynamics (4 papers), CRISPR and Genetic Engineering (2 papers) and Chromatin Remodeling and Cancer (2 papers). Alison Harrod is often cited by papers focused on Genomics and Chromatin Dynamics (4 papers), CRISPR and Genetic Engineering (2 papers) and Chromatin Remodeling and Cancer (2 papers). Alison Harrod collaborates with scholars based in United Kingdom, Hungary and Switzerland. Alison Harrod's co-authors include Simak Ali, R. Charles Coombes, Laki Buluwela, Manikandan Periyasamy, Jessica A. Downs, Luca Magnani, Hetal Patel, Van T.M. Nguyen, Daniela Barsotti Santos and Georgina P. Sava and has published in prestigious journals such as Nature Communications, Oncogene and Scientific Reports.

In The Last Decade

Alison Harrod

8 papers receiving 414 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alison Harrod United Kingdom	7	279	193	110	98	78	9	416
Holly M. Alley United States	9	266 1.0×	212 1.1×	199 1.8×	104 1.1×	144 1.8×	10	508
Leanna S. Morinishi United States	4	266 1.0×	148 0.8×	94 0.9×	140 1.4×	29 0.4×	5	406
Maike Roth United States	4	240 0.9×	144 0.7×	92 0.8×	128 1.3×	26 0.3×	4	377
Yulia Newton United States	8	371 1.3×	118 0.6×	171 1.6×	123 1.3×	80 1.0×	14	550
Alessandra Dall’Acqua Italy	10	270 1.0×	157 0.8×	92 0.8×	109 1.1×	25 0.3×	16	410
Michael E. Ramirez United States	4	284 1.0×	156 0.8×	99 0.9×	135 1.4×	29 0.4×	4	440
Amanda Balboni Iniguez United States	7	470 1.7×	207 1.1×	130 1.2×	75 0.8×	44 0.6×	7	604
Brendon Ladd United States	11	489 1.8×	109 0.6×	74 0.7×	106 1.1×	63 0.8×	19	584
Oihana Iriondo Spain	7	347 1.2×	278 1.4×	45 0.4×	161 1.6×	74 0.9×	9	518
Silvia Pomella Italy	14	511 1.8×	129 0.7×	122 1.1×	114 1.2×	35 0.4×	29	644

Countries citing papers authored by Alison Harrod

Since Specialization

Citations

This map shows the geographic impact of Alison Harrod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Harrod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Harrod more than expected).

Fields of papers citing papers by Alison Harrod

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Harrod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Harrod. The network helps show where Alison Harrod may publish in the future.

Co-authorship network of co-authors of Alison Harrod

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Harrod. A scholar is included among the top collaborators of Alison Harrod based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Harrod. Alison Harrod is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Simoes‐Sousa, Susana, Najaf Amin, Alison Harrod, et al.. (2025). ARID1A stabilizes non-homologous end joining factors at DNA breaks induced by the G4 ligand pyridostatin. Cell Reports. 44(9). 116277–116277.

Harrod, Alison, Theodoros I. Roumeliotis, Shane Foo, et al.. (2025). PBRM1 directs PBAF to pericentromeres and protects centromere integrity. Nature Communications. 16(1). 1980–1980. 3 indexed citations

Marchi, Tommaso De, Chun‐Fui Lai, Alison Harrod, et al.. (2024). Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling. Scientific Reports. 14(1). 6873–6873. 6 indexed citations

Harrod, Alison, Chun‐Fui Lai, Daniela Barsotti Santos, et al.. (2022). Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer. Oncogene. 41(44). 4905–4915. 17 indexed citations

Hu, Yunhui, Nahal Masrour, Alison Harrod, et al.. (2021). MicroRNA-495/TGF-β/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells. Biochemical Pharmacology. 192. 114692–114692. 18 indexed citations

Harrod, Alison, et al.. (2020). The role of the SWI/SNF chromatin remodelling complex in the response to DNA double strand breaks. DNA repair. 93. 102919–102919. 43 indexed citations

Patel, Hetal, Manikandan Periyasamy, Georgina P. Sava, et al.. (2018). ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Molecular Cancer Therapeutics. 17(6). 1156–1166. 111 indexed citations

Harrod, Alison, J Fulton, Van T.M. Nguyen, et al.. (2016). Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene. 36(16). 2286–2296. 131 indexed citations

Periyasamy, Manikandan, Hetal Patel, Chun‐Fui Lai, et al.. (2015). APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. Cell Reports. 13(1). 108–121. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact